The successes with chimeric antigen receptor (CAR) T cell therapy in early clinical trials
involving patients with pre-B cell acute lymphoblastic leukaemia (ALL) or B cell lymphomas …

Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies has surpassed
expectations, driving an ever-expanding number of clinical trials and the first US Food and …

A notable number of acute lymphoblastic leukemia (ALL) patients develop CD19-positive
relapse within 1 year after receiving chimeric antigen receptor (CAR) T cell therapy. It …

PURPOSE Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-
cell lymphoma (DLBCL) fare poorly, with limited treatment options. The antibody-drug …

Background Patients with diffuse large B-cell lymphoma that is refractory to primary and
second-line therapies or that has relapsed after stem-cell transplantation have a poor …

Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment for hematologic
malignancies. Two CAR T-cell products are now approved for clinical use by the US FDA …

The field of gene therapy is striving more than ever to define a path to the clinic and the
market. Twenty gene therapy products have already been approved and over two thousand …

Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cell has changed
the treatment landscape of B-cell non-Hodgkin's lymphoma (NHL), especially for aggressive …

By late 2018, 2 chimeric antigen receptor T (CAR T) cell products have been approved by
US and European regulatory authorities. Tisagenlecleucel (Kymriah, Novartis) is indicated in …

Chimeric antigen receptor (CAR) modified T cell therapy has revolutionized the treatment of
relapsed and refractory hematological malignancies. Through targeting of the CD19 antigen …